Valeant profit beats estimates as U.S. sales stay strong

Thu Jul 23, 2015 3:58pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

By Allison Lampert

MONTREAL (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc VRX.TO VRX.N reported a higher-than-expected quarterly profit on Thursday, helped by strength in its U.S. dermatology business, and its shares hit a record high.

The company also raised its full-year earnings and revenue forecasts to reflect sales of its new irritable bowel syndrome drug, Xifaxan.

U.S. regulators approved Xifaxan, also known as rifaximin, in May. Valeant acquired the drug with its $11 billion purchase of Salix earlier this year.

Valeant said it expected 2015 revenue of $10.7 billion to $11.1 billion, up from its prior outlook of $10.4 billion to 10.6 billion. It also raised its profit forecast to between $11.50 and $11.80 per share, excluding special items, from a prior range of $10.90 to $11.20.

Valeant shares were up more than 5.5 percent at C$329.43 in afternoon Toronto trading after touching a record high of C$330.69.

Under Chief Executive Michael Pearson, Valeant has grown rapidly through acquisitions, which included dermatology products such as sunscreen and anti-aging products.

Long-term debt has nearly doubled this year to just above $30 billion as of June 30.

In an interview, Pearson reiterated Valeant's commitment to reduce its leveraged ratio to less than four times adjusted pro-forma earnings before interest, taxes, depreciation and amortization by the end of 2016 from the current multiple of about 5.5.   Continued...

 
The company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval, Quebec May 19, 2015.   REUTERS/Christinne Muschi  -